Justin Kanoff, MD
Retina Specialist · Longmont, CONPI 1326205048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,255 and has fallen 56.4% since, to $548 in 2025. That places this record below the midpoint for retina specialist clinicians in CO, where the typical reported total is $4,083.
Across 143 payments — averaging $30.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$558
- Rxsight Inc$497
- Regeneron Healthcare Solutions, Inc.$486
- Genentech, Inc.$330
- Alcon$330
- Notal Vision, Inc.$281
- plus $2K from 25 others
Across 2 payments — averaging $4750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$10K
What the payments were for
- Speaking & faculty fees$2696%
- Food & beverage$4,12793%
- Entertainment$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 13 | $558 |
| Rxsight Inc | 4 | $497 |
| Regeneron Healthcare Solutions, Inc. | 19 | $486 |
| Genentech, Inc. | 15 | $330 |
| Alcon | 12 | $330 |
| Notal Vision, Inc. | 3 | $281 |
| Apellis Pharmaceuticals, Inc. | 11 | $261 |
| AbbVie(2 entities) | 13 | $201 |
| Novartis | 5 | $179 |
| Alimera Sciences, Inc. | 9 | $158 |
| Omeros Corporation | 2 | $142 |
| Dompe US, Inc. | 1 | $131 |
| Glaukos Corporation | 5 | $111 |
| Beaver-visitec International, Inc. | 1 | $102 |
| Carl Zeiss Meditec, Inc. | 1 | $95 |
| Bausch & Lomb Americas Inc. | 4 | $92 |
| Astellas Pharma US Inc | 3 | $80 |
| Biogen | 4 | $76 |
| Optos, Inc. | 3 | $56 |
| Coherus Oncology, Inc. | 2 | $41 |
| Harrow Eye, LLC | 2 | $38 |
| Spark Therapeutics, Inc. | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Eyepoint US, Inc. | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Lumibird Medical Inc. | 1 | $17 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,430 in reported general payments places this provider in the 50th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 20 | $7,755 |
| Prednisolone Acetate | 143 | $6,423 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 70 | $1,655 |
| Brimonidine Tartrate | 40 | $1,489 |
| Latanoprost | 123 | $1,476 |
| Ketorolac Tromethamine | 58 | $1,326 |
| ValacyclovirValacyclovir Hcl | 13 | $467 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 55 | $456 |
| Timolol Maleate | 64 | $416 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Longmont
- Matthew ManryLongmont$43K
- Carl NobleLongmont$3K
- William BenedictLongmont$599
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Ashleigh LevisonLafayette$33K
- Mimi LiuEnglewood$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.